Marinus Pharmaceuticals (MRNS)
(Delayed Data from NSDQ)
$1.41 USD
-0.02 (-1.06%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.40 -0.01 (-0.36%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Price, Consensus and EPS Surprise
MRNS 1.41 -0.02(-1.06%)
Will MRNS be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for MRNS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MRNS
Marinus (MRNS) Down 83% on Lead Drug Falling Short in Seizure Study
Do Options Traders Know Something About Marinus (MRNS) Stock We Don't?
MRNS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Marinus Pharmaceuticals (MRNS) Reports Q4 Loss, Lags Revenue Estimates
Amneal Pharmaceuticals (AMRX) Beats Q4 Earnings Estimates
Strength Seen in Catalent (CTLT): Can Its 9.7% Jump Turn into More Strength?
Other News for MRNS
Biotech Alert: Searches spiking for these stocks today
Marinus Pharmaceuticals price target lowered by $15 at Truist, here's why
Analysts’ Top Healthcare Picks: Inspire Medical Systems (INSP), Eli Lilly & Co (LLY)
Maintaining Buy Rating on Marinus: A Balanced View on Future Prospects Despite RSE Setback
Biotech Alert: Searches spiking for these stocks today